Castle Biosciences (CSTL) on Sunday reported data from studies backing the "clinical utility" of its DecisionDx-Melanoma and DecisionDx-SCC tests in guiding treatment paths in patients with scan cancer.

The treatment options include sentinel lymph node biopsy for patients with melanoma and surveillance imaging for those with squamous cell carcinoma of the skin.

Etan Marks, a pathologist and author of one of the studies, said they showed the Castle Biosciences tests provide physicians and patients insights that "enhance clinical decision-making and arm clinicians with more precise risk information to help route patients to the most appropriate modality aligned to their risk of metastasis and survival."

The company said the gene expression profiling and risk stratification tests show which patients are at lower risk and able to forgo certain tests.